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Hormone Secretion and Alterations in the Gut Microbiota
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ABSTRACT Rising rates of obesity and type 2 diabetes have prompted the usage and recommendation
of nonnutritive sweeteners (NNS) as harmless sugar substitutes in attempts to decrease caloric intake.
Contrary to the common belief that NNS remain physiologically inert post-consumption, evidence
highlights their ability to alter metabolic processes via interactions in the gastrointestinal tract. An
extensive review was conducted on the potential NNS-induced metabolic deviances by way of two nonmutually exclusive mechanisms. One possible mechanism involves their ability (or inability) to induce
the secretion of GLP-1, a hormone produced in the gut that promotes satiety and accelerates glucosedependent insulin secretion by interacting with sweet-taste receptors in the small intestine. Though NNS
(sucralose, Ace K, and Rebaudioside A) show a high rate of GLP-1 secretion during in vitro studies,
there are many discrepancies in results from human in vivo studies. A second mechanism proposes that
NNS alter the composition of the gut microbiota, a vast community of microorganisms responsible for
digesting food, releasing metabolites, and synthesizing vitamins. Differing forms of dysbiosis,
alterations in bacterial composition, are observed, including an increased ratio of Firmicutes to
Bacteroidetes and an increase in Lactobacilli spp. in exclusive studies, upon NNS exposure. Few
experiments assessing NNS impact on the gut microbiota have been conducted with human subjects.
Further investigations, specific to human subjects, should be explored in order to assess the true extent
to which NNS impact incretin secretion and alterations in the gut microbiota.

INTRODUCTION
In recent decades, the usage and implementation
of high-sugar content food products have
accelerated the presence of metabolic syndromes

like obesity and diabetes (Low et al., 2016). If
current trends in diet and lifestyle continue to
accelerate, an estimated 38% of the world’s
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population will be overweight and another 20%
will be obese by the year 2030 (Smith et al.,
2016). Abnormally high consumption rates of
energy-dense foods with large contents of sugars
and saturated fats not only serve as a leading
cause for obesity but also contribute largely to
type 2 diabetes, hypertension, and cardiovascular
disease (Laffitte et al., 2014). In attempt to
diminish the overbearing and unhealthful trends
in diet, substitutes for sugars, nonnutritive
sweeteners (NNS), have been developed. NNS
can deliver a high potency content of sweetness
in a miniscule concentration with negligent
caloric intake by binding with strong affinity to
one or more sites on the sweet taste receptor in
the oral cavity (Burke et al., 2015). Until recent
consideration, NNS were recommended for
people who were approaching obesity and/or
onset diabetes to aid in health improvement by
providing a sweet taste without affecting caloric
intake and glycemic responses; however, on
accounts of multiple studies, NNS consumption
over a prolonged period of time may promote
glucose intolerance, obesity and its associative
commodities (Nettleton et al., 2016). Currently,
the FDA has recognized six NNS for use in the
United States: acesulfame potassium, aspartame,
neotame, saccharin, sucralose, and Rebaudioside
A. The presence of these sweeteners has
dominated many components of our diet and
personal care products including “diet” or “zerocalorie” drinks, chewing gum, toothpaste, and
many other foods and drinks for enhancement of
flavor (Sylvetsky et al., 2017). The discovery of
sweet taste receptors in the gut has prompted the
possibility for NNS to interact with them in a
similar fashion to which they bind to the taste
receptors in the oral cavity (Laffitte et al., 2014;
Margolskee et al., 2007; Pepino et al., 2011).
Contrary to the common belief that NNS are
physiologically inert compounds, there is
overwhelming evidence that highlights their
ability to alter metabolic processes that control
homeostasis post-consumption via interactions in
the gastrointestinal tract. This review focuses on
the impact of NNS on the secretion of satiety
hormone glucagon-like peptide-1 (GLP-1) and
NNS-induced alterations in the gut microbiota. In
terms of evolution, the highly innate sensation
and perception of taste has provided vertebrates
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with an expansive pallet capable of detecting
beneficial and toxic nutrients, thus enabling them
to successfully navigate their surroundings. Most
notably, the innate preference to sweet taste
evolved to detect the presence of valuable
carbohydrates, and the interactions between
sweeteners and sweet taste receptors (in the oral
and extra oral cavities) predict caloric content and
evoke physiological responses that prepare the
gastrointestinal tract for digestion according to
the intensity and quantity (Pepino et al., 2011).
The gastrointestinal tract is home to an elaborate
network of enteroendocrine cells that release
hormones to signal digestive, homeostatic, and
behavioral responses by responding to the enteric
nervous system and effectively communicating to
target organs. One of these processes involves the
secretion of a satiety hormone, GLP-1 which
serves a vital function by amplifying glucosedependent insulin secretion (Baggio et al., 2007;
Jang et al., 2007; Takai et al., 2015).
A large part of the human metabolism is
dependent on the gut microbiota for processing
food that would otherwise be indigestible and
synthesizing valuable vitamins, such as vitamin
B12 (D’Argenio et al., 2015). Additionally, the
gut microbiota has been identified as a key player
in the intricate mechanisms of nutrient
metabolism in the gut and in the neuronal
communication and regulation of the
hypothalamic-pituitary-adrenal axis (Sudo,
2014). Though the recently proposed
mechanisms of such interactions are not
definitive, their presence and predicted impact
makes the microbiome a likely contributor to
metabolic syndrome. Metabolic syndrome is
characterized by a combination of three or more
of the following symptoms: abdominal obesity,
high triglycerides, low high-density lipoproteincholesterol (HDL-C) and heightened blood
pressure and blood sugar (Sudo, 2014). Those
affected by metabolic syndrome are subject to a
significant increase risk to cardiovascular
disease, diabetes mellitus, non-alcoholic fatty
liver disease, polycystic ovarian syndrome,
dementia, and cancer. A predicted contributor
and common characteristic of metabolic
syndrome is chronic inflammation which can be
attributed by various environmental and genetic
factors (Melvin et al., 2016). One such

2

Decker: Potential Mechansisms for NNS-Induced Metabolic Deviances

environmental factor includes alterations in the
gut microbiota. Changes in gut bacterial
composition have been linked to inflammatory
side-effects that promote insulin resistance, fat
storage and weight gain in the host which makes
it a potential contributor to the development of
metabolic syndrome, obesity and/or type 2
diabetes (Daly et al., 2014; Palmnäs et al., 2014).

secretion and the gut microbiota, several
mechanisms will be proposed that enable these
discrepancies and serve as prospective points of
interest for future research on metabolic health.
The directionality of this review is provided by a
study outline (see Figure 1).

Being that both metabolic components, gut
hormone secretion and the gut microbiota, are
localized in the gastrointestinal mucosa and
enteric nervous system, they are likely to have
intersecting impacts when affected by NNS.
Specifically, recent studies have indicated that
the gut bacterial composition can affect the
development and regulation of the hypothalamicpituitary-adrenal axis and behavior via
mechanisms of gut hormone secretion (Sudo,
2014). Additionally, host-derived satiety
hormones were found to increase local bacterial
proliferative capacity as well as pathogenicity
(Sudo, 2014). The interactive communication
between the microbiome and enteroendocrine
cell hormone secretion reveals their non-mutually
exclusive relationship and has further
implications when assessing their response to
NNS. Though the mechanistic connection
between the two are not solidified, both aspects
serve as important targets individually when
assessing the metabolic impacts of NNS. In
exploring the impact of NNS on satiety hormone

PubMed database searches were carried out using
keywords and phrases relevant to this review:
non-nutritive sweeteners, gut hormones, GLP-1,
GIP, gut microbiota, body-weight, insulin,
homeostasis, and glucagon. Searches were
filtered by “Best Match,” and their publishing
dates were considered in order to include the most
current information.

METHODS

RESULTS
POTENTIAL MECHANISMS FOR NNSINDUCED METABOLIC DEVIANCES
1.a. Gut Function: The Enteroendocrine System
The gastrointestinal tract consists of a series of
hollow organs that enable the breakdown,
metabolism, and distribution of nutrients ingested
from the environment. Specific to the gut, the
enteric nervous and enteroendocrine systems
work together to initiate digestion and effectively
communicate proper metabolic signals (via gutderived peptides) to the brain to commence

Figure 1. Study Overview. Outlined above, the direction of the review began with a general concern for NNS
and their impact on metabolic process then succinctly moved toward their impact on satiety hormone secretion
and the gut microbiota. Studies marked with “*” were conducted in vitro.

Published by Digital Commons@DePaul, 2018

3

DePaul Discoveries, Vol. 7 [2018], Iss. 1, Art. 5

chemical and behavioral responses. Sensory
neurons in the gastrointestinal tract partake in
homeostasis, danger detection, and protective
responses by communicating with surrounding
intestinal cells (Melvin et al., 2016). The
gastrointestinal tract produces a vast amount of
peptide hormones that initiate specific responses.
Specialized cells in the gastrointestinal tract,
enteroendocrine cells, are responsible for the
endocrine action of the gut (Melvin et al., 2016).
During periods of fasting, ghrelin is released by
specific enteroendocrine cells found in the gastric
fondus. In contrast, leptin, produced by adipose
cells, inhibits hunger and regulates long-term
energy storage (Melvin et al., 2016).
Additionally, a high presence of lipid initiates
peptide YY (PYY) secretion in enteroendocreine
cells in the ileum and results in a reduction in
caloric intake (30%) (Melven et al., 2016). Also
termed as “incretins,” gut hormones, GLP-1 and
gastric inhibitory polypeptide (GIP), are directly
involved in the transmission of sweet-taste
signals from carbohydrates by accelerating
glucose-dependent insulin secretion in pancreatic
ß-cells (Henquinn et al., 2012; van der Wielen et
al., 2016). GLP-1, the more influential of the two,
is secreted by intestinal L cells located in the
gastrointestinal mucosa and acts locally within
the intestinal wall to initiate enteroenteric
reflexes which slow the rate of gastric emptying
(Nadkarni et al., 2014). Additionally, GLP-1
regulates glucose homeostasis by inhibiting the
release of glucagon, therefore decreasing the
breakdown of glycogen and lowering blood
glucose levels (van der Wielen et al., 2016). For
these reasons, GLP-1 has been actively
researched as a possible target for the treatment
and prevention of obesity and type 2 diabetes.
The relationship and communication between
intestinal L cells and pancreatic -cells via
incretins to secrete insulin has been dubbed the
incretin effect. It was discovered that oral glucose
administration promoted substantially greater
amounts of insulin secretion compared to an
intravenous injection of glucose, indicating the
role of incretins in amplifying insulin secretion
(Delgado-Aros et al., 2002; Swithers et al., 2013).
Incretins are estimated to account for 50-70% of
the total insulin production post-meal
consumption (Steinert et al., 2011). Considering
the direct correlation with enhanced insulin
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secretion, inhibition of glucagon release, and
promoted feelings of satiety, GLP-1 is a vital
messenger examined.
1.b. The T1R2/T1R3 Taste Receptor Expressed
In Extraoral Tissues
NNS have the unique ability to elicit a sweet-taste
response that ranges between 100-800 times
sweeter than an equivalent amount of glucose,
thus allowing their implementation for food/drink
product to be miniscule. Due to their unique
chemical structure, the predicted mechanism for
the heightened response is an increase in bonding
affinity for the sweet taste receptor. Sweet taste
perception is initiated in the oral cavity by the
binding of a sweet-tasting molecule to a sweet
taste receptor, a G-protein coupled receptor with
two 7-transmembrane subunits, taste receptor
type 1 member 2 and taste receptor type 1
member 3 (T1R2/T1R3) (Burke et al., 2015). The
heterodimeric receptor provides input on the
caloric contents of ingested food by initializing
cellular and neural responses when in contact
with natural sugars or non-nutritive sweeteners
(Laffitte et al., 2014). Within the last 5 years, the
T1R2/T1R3 sweet taste receptor and its
associated taste signal transduction molecules
have been discovered in tissues beyond the
mouth, including the gastrointestinal tract,
pancreas, adipose tissues, and brain (Kyriazis et
al., 2012; Laffitte et al., 2014; Nakagawa et al.,
2009; Oya et al., 2011; Takai et al., 2015). The
presence of such receptors in tissues beyond the
oral cavity suggests an additional physiological
purpose than simply sweet-taste detection;
Specific to the intestinal tract, the T1R2/T1R3
receptors, integrated within the membrane of
enteroendocrine cells, trigger physiological
responses that facilitate metabolic processes and
stimulate glucose absorption (Margolskee et al.,
2007; Sclafani et al., 2007; Shirazi-Beechey et
al., 2011). Glucose absorption in the gut is
essential for the host as nutrients from food must
be transferred from the gut into the bloodstream
for delivery to target organs. Significant evidence
supports that glucose uptake via sodiumdependent glucose transporter isoform 1
(SGLT1) in enteroendocrine cells is regulated, to
a degree, by the activation of the T1R2/T1R3
receptors and their related components of G-
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protein-linked signaling pathways (i.e. gutducin, phospholipase C  type 2, and transient
receptor potential channel M5 [TRPM5]) (Jang et
al., 2007; Margolskee et al., 2007; Merigo et al.,
2011; Rozengurt et al., 2006). Margolskee et al.,
and others have demonstrated that knockout mice
lacking T1R3 or -gustducin were not able to
increase SGLT1 mRNA and protein expression,
whereas mice with the components significantly
elevated expression of SGLT1 upon consumption
of sugars or artificial sweeteners, indicating that
the heterodimeric sweet taste receptor had an
influence on glucose uptake in mice.
The main function of enteroendocrine cells is to
produce and secrete gastrointestinal hormones,
incretins, which act as local messengers and aid
in digestive processes (Baggio et al., 2007). The
two incretins, GLP-1 and gastric inhibitory
polypeptide (GIP), also relay information to
sensory neurons in close proximity via enhancing
secretion neurotransmitters (Nadkarni et al.,
2014). Incretins, hormones that facilitate the
rapid digestion of ingested nutrients, are released
within minutes of meal consumption by
enteroendocrine cells in the small and large
intestine (Baggio et al., 2007; Delgado-Aros et
al., 2002; Nadkarni et al., 2014). Similar to
glucose uptake via SGLT1, GLP-1 secretion is
initiated, at least partially, by the activation of the
T1R2/T1R3 receptors in the small intestine
(Takai et al., 2015).
1.c. The Initiation of T1R2/T1R3 Receptor,
GLP-1 Secretion, and Glucose-Dependent
Insulin Release
There is functional evidence linking the
T1R2/T1R3 taste receptor and the release of
incretins in enteroendocrine cells; however, a
definite mechanism has not been developed.
Having discovered the same components
involved in the perception of taste in type II taste
cells in the tongue, one proposed mechanism
mirrors this same pathway. As seen in Figure 2,
the secretion of incretins (GLP-1 & GIP) is
stimulated by the signal transduction pathway
initiated at the T1R2/T1R3 receptor. In type II
taste cells in the oral cavity, stimulation of the
T1R2/T1R3 receptor causes the dissociation of
the heterotrimeric guanine-nucleotide-binding G

Published by Digital Commons@DePaul, 2018

protein and its,, and  subunits (-gustducin,
G3, and G13). This dissociation leads to an
increase in phospholipase C-2 (PLC-2) activity
which causes the inositol 1,4,5-triphosphate (IP3)
receptor to release Ca2+ from intracellular stores
and the opening of transient potential ion channel,
transient receptor potential cation channel
subfamily M member 5 (TRPM5). As a result, the
membrane is depolarized, and an action potential
is generated, causing a release of adenosine
triphosphate (ATP) which acts as a transmitter for
further gustatory afferents.
Though the mechanism has not been directly
proven, eneteroendocrine cells are thought to
follow a similar pathway involving the
T1R2/T1R3 receptor and the heterotrimeric G
protein (-gustducin, G3, and G13) and the
resulting depolarization of the cell membrane
(Behrens et al., 2011; Gheni et al., 2014; Wu et
al., 2013). Instead of continuing the transmission
of gustatory sensory information from the tongue
to the brain, the action potential generated in the
enteroendocrine cells facilitates the release of
hormone-containing vesicles. Further, GLP-1 and
GIP, are able to effectively aid in post-digestive
responses. In a study conducted by Jang et al.
(2007), -gustducin or T1R3 knockout mice did
not show an increased secretion of GLP-1 to
direct glucose ingestion. Additionally, GLP-1
secretion in L cells was significantly lower in
mice exposed to a T1R2/T1R3 receptor inhibitor,
lactisole. Together, their results indicate that taste
receptor components in enteroendocrine cells are
directly involved in the secretion of GLP-1 in
mice.
The two dominant signals that drive insulin
secretion in pancreatic  cells are generated ATP
via glucose metabolism and the influx of Ca2+
ions. ATP generated by glucose metabolism
closes the ATP sensitive K+(KATP) channels,
depolarizing the cell membrane. Voltagedependent Ca2+ channels open, allowing the
influx of Ca2+ and exocytosis of insulin granules
(Côté et al., 2014; Gheni et al., 2014;). Incretins,
GLP-1 and GIP, act as paracrine signaling
molecules by interacting with G-protein coupled
receptors (GPCRs) to accelerate insulin secretion
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Figure 2. GLP-1 Secretion via T1R2/T1R3 Receptor. The intracellular mechanism outlined in the above figure
provides a possible relationship between the intracellular cascade observed in type II taste cells and enteroendocrine
cells in the gut. The mechanism in the taste buds is as follows: T1R2/T1R3 receptor stimulation; dissociation of the
heterotrimeric guanine-nucleotide-binding G protein and , , and  subunits (-gustducin, G3, and G13); increase
in phospholipase C-2 (PLC-2); inositol 1,4,5-triphosphate (IP3) receptor releases Ca2+ from intracellular stores;
opening of transient receptor potential cation channel subfamily M member 5 (TRPM5); membrane depolarized; action
potential built; release of ATP. Enteroendocrine cells are predicted to follow a similar pathway via stimulation of the
T1R2/T1R3 receptor where the action potential from Ca2+ built up acts as the driving force for the secretion of incretins,
gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1(GLP-1). Upon stimulation of the T1R2/T1R3 receptor
via sweet-tasting molecule, incretins are released, and the expression of sodium-glucose transporter-2 (GLUT-2)
increases. This figure (Lafitte et al., 2014) has been reproduced with permission from Wolters Kluwer Health, Inc.

in a glucose-dependent manner via cyclic AMP
(cAMP) signaling; however, this phenomenon is
not presented in Figure 2. Proposed by multiple
sources, a possible mechanism for the amplifying
effects of incretins on insulin secretion links
glutamate,
a product of the malate-aspartate
figure
(MA) shuttle, as the key factor for combination
(Côté et al., 2014; Gheni et al., 2014). Upon
stimulation of a specific G protein in the
membrane of a pancreatic  cell via an incretin
molecule, cAMP/protein kinase A signaling
allows insulin granules to uptake glutamate
produced from the malate-aspartate shuttle,
thereby increasing the secretion of insulin.

https://via.library.depaul.edu/depaul-disc/vol7/iss1/5

1.d. Satiety Hormone Secretion via T1R2/T1R3
Receptor: NNS Glucose Structural Analogy and
Macronutrient Pairing
Nonnutritive sweeteners have been predicted to
elicit a response, similar to glucose, which
potentiates levels of GLP-1; however, many
studies dealing specifically with human subjects
saw no response to predicted incretin levels,
indicating a deficiency in the release of incretins
via enteroendocrine cells. Incretins’ ability to
potentiate insulin secretion, promote satiety, and
prolong gastric emptying make them a critical
component to glucose regulation and

6

Decker: Potential Mechansisms for NNS-Induced Metabolic Deviances

consumption
patterns.
Several
studies,
summarized in Table 1, assessed the implications
of various NNS (sucralose, acesulfame
potassium, aspartame, and Rebaudioside A) and
polyol sweeteners (erythritol and exylitol) on
GLP-1 secretion.
While focusing on studies dealing with human
subjects, the experiments done in vivo were
discordant in their findings. Wölnerhanssen et al.
(2016) found that xylitol and erythritol, polyol
sweeteners, caused a significant increase in GLP1 levels in both lean (5) and obese (5) subjects
compared to a control, an intragastric infusion of
just water. Methods that delivered treatments via
intragastric infusion involved a catheter tube that
allowed for direct administration to the
duodenum, bypassing the digestive processes that
occur prior. Additionally, administering a
“glucose load” consisted of consuming 75 g of
glucose after NNS exposure. Polyols are not
technically nonnutritive because they are
partially metabolized, but over 90% of erythritol
is absorbed then excreted by the kidney, and
xylitol is readily fermented by bacteria in the gut.
Hence, their actual caloric intake is much lower
than that of glucose. With no prior intake or
glucose administration, insulin levels remained
low, indicating the glucose-dependent nature of
insulin secretion. It is worthy to note that this

study used extremely high amounts of sweetener
in their infusions (50g of xylitol and 75g of
erythritol), which are unrealistic to typical
consumption amounts as these usually appear in
lower concentrations. The structural similarity
between polyols and glucose was a proposed
cause for the increased levels of GLP-1. Two
other studies that followed a similar intragastric
infusion method in human subjects; Ma et al.
(2009) and Steinert et al. (2011) observed no
difference in GLP-1 levels upon sucralose,
aspartame,
and
acesulfame
potassium
administration. Steinert et al., suggested that the
secretion of GLP-1 depended more than just the
detection sweetness or that it was reliant on a
structural analogy to glucose. Rather than using
infusions, many in vivo studies assessed NNS
impact on GLP-1 by method of a dissolved drink,
either commercial diet sodas or custom
concoctions. This method more accurately
represents the physiological conditions in which
NNS would exist as the quantities of
administered NNS were lower and the digestive
path incorporated all components of the
gastrointestinal tract. In doing this, they all also
administered a 75g oral glucose tolerance test
(OGTT) 10-15min after exposure to NNS to test
responses to GLP-1, insulin, and blood glucose
levels. Temizkan et al. (2015) administered
sucralose to normal and diagnosed type 2 diabetic

Table 1. Summarized Results of NNS Impact on GLP-1 Secretion.
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subjects and found that it enhanced GLP-1 levels
in only healthy subjects. Additionally, they saw
lower levels of blood glucose in the normal
patients after NNS introduction compared to the
control (water). This study highlights the
metabolic deficiencies in diabetic patients and
proposes NNS as possible targets for prevention
of this onset disease. Brown et al. (2009) saw a
greater increase in GLP-1 levels after drinking
240mL diet soda (sweetened with sucralose and
Ace K) compared to the control (carbonated
water). They concluded that NNS has an
enhancing effect on the GLP-1 release by
synergizing with glucose. With aims to clarify the
real impact of NNS on GLP-1 release, a study
conducted by Wu et al., conducted similar
conditions; however, instead of using a
commercial diet soda, they used pure sucralose
and Ace K dissolved in water with no added
substances found in the diet soda used by Brown
et al. (caramel color, gum acacia, natural flavors,
citric acid, potassium benzoate, phosphoric acid,
and potassium citrate). Their results yielded no
difference in GLP-1 secretion when exposed to
NNS versus the control (water). These two
studies, Brown et al. and Wu et al. (2009), present
the possibility that the added components found
in the diet soda that Brown et al. used could have
contributed, in combination with NNS, to the
enhancing effect of GLP-1 more so than the NNS
alone.
Approximately half of the in vivo studies
observed an increase in GLP-1 levels, whereas
the other half saw no increase. The majority of the
results are not in complete agreement; however,
there is moderate evidence suggesting that NNS
can an impact GLP-1 secretion within in vivo
experimentation. The experiments conducted in
controlled cell lines (in vitro) were more
congruent in their findings. Geraedts et al. (2012)
took eight healthy human mucosal tissue samples
from the duodenum via gastroduodenoscopy and
found that sucralose and Ace K alone could
induce GLP-1 secretion, but their effects were
enhanced when pea protein was added in
combination to the cell lines. In agreement with
Brown et al., they deduced that NNS sucralose
and Ace K may synergize with a macronutrient to
enhance satiety hormone secretion. Jang et al.
demonstrated a positive correlation between NNS

https://via.library.depaul.edu/depaul-disc/vol7/iss1/5

sucralose and GLP-1 secretion in post mortem
human duodenum cell lines. When lactisole, a
known sweet receptor inhibitor was introduced,
the secretion of GLP-1 was diminished,
supporting the hypothesis that involves the
T1R2/T1R3 sweet taste receptor and incretin
release. In derived mouse cell lines, van der
Wielen et al. (2016) also observed a clear increase
in GLP-1 secretion (4.3 fold in the ileum) when
directly exposed to Rebaudioside A. More so than
the in vivo experiments, the in vitro studies
provide evidence for a direct correlation between
the stimulation of the T1R2/T1R3 receptor and
GLP-1 secretion. Remarkably, they proved that
NNS can induce this pathway; however, in vitro
experiments are restricting in their results due to
the controlled setting and limiting factors.
NNS DISRUPT THE GUT MICROBIOTA
COMPOSITION
2.a. The Importance of the Gut Microbiota on
Metabolism
The human gut microbiota, consisting of mostly
bacteria (>90%), archaea, viruses, and unicellular
organisms, is linked to physiological and
digestive capacities that humans have yet to
evolve independently. Specific to the intestinal
tract, the gut microbiota aids in detoxification,
vitamin synthesis, immunity, and digestion by
secreting enzymes for substances otherwise nondigestible (D’Argenio et al., 2015). Alterations in
the gut microbiome have been linked to abnormal
metabolic deficiencies as well as obesity,
diabetes, and chronic inflammation (Philippaert
et al., 2017). These alterations can be stimulated
by internal and external factors including diet,
age, hormonal cycles, therapies, and illness. It is
important to note that the composition of
microflora within host species develops from
distinct selective pressures and inherited genetic
factors; therefore, the composition will differ
significantly from person to person and even
more so from humans to other mammals (mice,
swine, and rats) (Daly et al., 2014). Disruptions
in the gut microbiota are widely recognized as an
operative contributor that lead to the development
of obesity and insulin resistance (Nettleton et al.,
2016). Consisting of 400-1000 adherent and nonadherent bacterial species, the majority of the
bacteria in the microbiome (>90%) belong to one
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of the two major phyla, the Firmicutes and the
Bacteroidetes (Nettleton et al., 2016; Philippaert
et al., 2017). A convincing, but not definite,
characteristic of obesity and type II diabetes is
associated with a high ratio of Firmicutes to
Bacteroidetes (Drasar et al., 1972; Nettleton et
al., 2016; Palmnäs et al., 2014). The ratio between
them is thought to influence metabolic processes
and susceptibility to onset metabolic syndrome
(Nettleton et al., 2016), but due to the specificity
and variability of microbiomes, this ratio has
been questionable as plenty of healthy patients
showed high ratios of Firmicutes to Bacteroidetes
and vice versa (Frankenfeld et al., 2015). In
accordance with these recent findings, the impact
of NNS on the gut microbiota has gained serious
attention.
2.b. NNS-Induced Disruptions in the Gut
Microbiota via Membrane-Spanning Receptors
and Production of SCFA
Literature research on NNS and the gut
microbiota yielded very few studies that failed to
disprove their null hypothesis, but the majority of
the experiments conducted were carried out with
non-human mammals as their subjects. The core
studies are summarized in Table 2 and are
referenced throughout the text, ranging from
results that showed NNS to be harmful (impaired
metabolic responses), beneficial, or non-affecting
to the function of metabolic responses.
Additionally, a supplementary figure, detailing
the taxonomic classification of bacteria involved
in the following studies, was developed to display

the relationship between bacterial species and
their predicted metabolic impacts (see Figure 3).
Palmnäs et al. (2014) assessed the effect of lowdose aspartame on the microbiome composition
and glycemic responses on male Sprague-Dawley
rats. They found that aspartame-consuming rats
consumed fewer calories and gained less weight
than the control diet (water); however, the
aspartame group displayed elevated fasting
glucose levels and impaired insulin-stimulated
glucose disposal. Analysis of their microbiome
composition revealed an increase in the
Firmicutes to Bacteroidetes ratio, specifically,
overall increases in the abundance of
Enterobacteriaceae, Roseburia, and Clostridium
leptum. In addition, they observed increased
amounts of the short chain fatty acid (SCFA)
propionate, a highly gluconeogenic substrate, in
the aspartame-consuming group. The rising
abundance of SCFA propionate was most likely a
result of the increase in Clostridium spp. as it
produces this metabolite during fermentation
(Puertollano et al., 2014). This study shows the
possibility of NNS interacting with bacteria in the
gut to induce production of a bacterial end
product, SCFA propionate, which is known to
impair insulin function and elevate glucose levels
(Palmnäs et al., 2014; Ximenes et al., 2007). Suez
et al. also observed a NNS-induced glucose
intolerance and attributed it to alterations in the
gut microbiota. Exposure to NNS saccharin in
mice
lead
to
increasing
levels
of
Enterobacteriaceae, Bacteroides, and some

NGS = Next-Generation Sequencing.
qPCR = Quantitative polymerase chain reaction assay

Table 2. Summarized Results of NNS Impact on the Gut Microbiota.
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Clostridiales, and decreasing amounts of
Lactobacilli spp. and other Clostridiales. These
bacterial compositional characteristics were
accompanied by increased glycemic responses.
After introducing antibiotic A (ciprofloxacin and
metronidazole) and antibiotic B (vancomycin),
the glycemic responses returned to normal levels
that were comparable to the control group
(water), suggesting that the changes in bacteria
abundance were directly responsible for the
impaired glycemic response. Failing to do an
analysis of the microbiome post-antibiotic
treatment, this study did not determine what
differentiated between the two microbiome
compositions. In an additional phase, they
introduced saccharin treated bacterial colonies
from affected mice and 7 humans to germ-free
mice and saw similar trends in their rising blood
glucose levels, verifying the importance of the
gut microbiota composition on glucose
homeostasis.
Possible mechanisms for the
alterations in bacteria and the resulting glycemic
responses were not identified in this study.
Frankenfeld et al. (2015), one of the few studies
dealing with human subjects, assessed fecal
bacterial composition upon exposure to
aspartame and Ace K. They found no significant
alterations in composition makeup (See Table 2).
In contrast to the previous studies, Daly et al.
(2014) demonstrated a scenario in which

commercial NNS SUCRAM™ (saccharin/
NHDC) was beneficial to swine hosts by
increasing the amounts of anti-inflammatory and
immune-protecting Lactobacillus. Consisting of
two experimental groups (standard wheat diet
plus lactose or SUCRAM™) and a control group
(standard wheat diet), they found a significant
enhancement of caecal Lactobacillus populations
in the lactose and SUCRAM™-exposed swine
groups. Lactobacillus grow anaerobically by
fermenting sugars to produce lactic acid, a
metabolic product that was found in noticeably
larger quantities in their experimental groups. In
order to maximize their fermentation capacities,
Lactobacillus have evolved multiple sugar
transport and metabolic systems, which are
initiated at their receptors by substrates (Daly et
al., 2014). In the conclusion of their study, they
proposed that certain members of the genus
Lactobacillus have specific membrane-spanning
receptor proteins that interact with one or both of
the components of SUCRAM™, saccharin and/or
neohesperidin dihydrochalcone (NHDC), to
induce rapid growth in a similar way that lactose
would. In a follow up study, Daly et al. narrowed
the exact Lactobacilli species (Lactobacillus
4228) responsible for the highest rates of growth
and determined the cause of the proliferation to
be a result of a reduced lag-phase in cell division
(Daly et al., 2016). In vitro analysis revealed that
NHDC (one component of SUCRAM™) was

Figure 3. Taxonomic Classification of Notable Bacteria Impacted by NNS. Groups outlined in green are
predicted to have a positive impact on metabolic and glycemic responses when abundance is increased. In
contrast, those outlined in red are predicted to have negative impacts on metabolic processes when abundance is
increased. An increased ratio of phyla Firmicutes : Bacteroidetes is associated with various metabolic
deficiencies, such as type II diabetes and obesity, and can be visualized in the figure.
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held most responsible for the accelerated growth
patterns, confirming NHDC as the substrate for a
specific membrane-spanning receptor protein.
NNS NHDC is not approved for use in the United
States; however, it is generally recognized as safe
by the FDA.
CONCLUSIONS
NNS have established a strong presence in the
common diet and continue to surround us in areas
beyond perceived ingestion such as personal care
products like toothpaste (Sylvetsky et al., 2017).
As they are regularly recommended to
individuals either prone to or experiencing
metabolic deficiencies due to their non-caloric
reputation, their impact post-consumption should
be further examined due to the overwhelming
evidence that supports the notion that NNS are
likely metabolically active. While comparing
studies that used different NNS and
concentrations, species of subjects, and
administrative processes (i.e. in vitro vs. in vivo),
it is essential to consider their experimental
differences as a contributor to their disagreement
in results. The evidence surrounding the NNSinduced secretion of GLP-1 are consistent in most
in vitro studies conducted with both human and
other mammalian cell lines, supporting the
hypothesis that NNS (sucralose & Ace K) interact
with the T1R2/T1R3 taste receptor to aid in GLP1 secretion (Geraedts et al., 2012; Jang et al.,
2007; van der Wielen et al., 2016). Additionally,
xylitol and erytrhitol, two sweeteners that are not
technically nonnutritive, potentiated GLP-1
levels at high concentrations in vivo possibly due
to their structural similarity to glucose
(Wolnerhanssen et al., 2016). Contrary to this, the
majority of studies done in vivo on humans
determined that NNS (sucralose and Ace K)
could not potentiate GLP-1 secretion
independently (Ma et al., 2009; Steinert et al.,
2011; Temizkan et al., 2015; Wu et al., 2013), and
those that saw increased GLP-1 levels deduced
that a synergistic effect between NNS and a
macronutrient caused the enhanced incretin
secretion (Brown et al., 2009). This intensified
release of GLP-1 via NNS and macronutrients in
combination was supported in Geraedts et al.
where they observed significantly higher
amounts of GLP-1 secretion when pea protein
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was added to cell lines affected by sucralose and
Ace K (Geraedts et al., 2012). As NNS are
commonly consumed in combination with a meal
in hopes of reducing sugar content, the pairing of
NNS and macronutrient will likely induce
secretion of GLP-1 and elicit an uptake response
similar to that of glucose. In contrast, an inability
for NNS to trigger post-ingestive responses, such
as the secretion of GLP-1, can influence
downstream digestion in a negative manner
where conditioned response would be disrupted
and secretion levels of insulin would be reduced;
therefore, further experimentation is necessary to
determine their definite effect on the secretion of
satiety hormone, GLP-1.
Dysbiosis in the human gut microbiota is now
considered a legitimate cause and characteristic
of people either approaching or exemplifying
obesity (David et al., 2014; Turnbaugh et al.,
2006). The majority of studies assessing the
effect of NNS on the gut microbiome
composition observed some degree of dysbiosis.
One damaging result of the dysbiosis after
aspartame consumption in rats, observed by
Palmnäs et al. (2014), increased the production of
SCFA propionate, a gluconeogenic substrate, via
Clostridium spp. Propionate impairs insulin
function and elevates glucose levels, creating a
detrimental environment for someone attempting
to avoid obesity and type 2 diabetes. In converse,
Daly et al. (2016) observed a positive form of
dysbiosis by the increase in beneficial
Lactobacillus spp. in saccharin and NHDC
induced swine. The specific cause of increase in
Lactobacilli population was attributed to a
reduced lag-phase induced by NHDC, a NNS
component of commercial SUCRAM™.
Altogether, the evidence presented in this review
highlights the conflicting results regarding NNS
and their integration into diet; NNS and their
impact on hormone secretion and the gut
microbiome require additional research to
succinctly link their relationships. In combatting
obesity and diabetes, these two non-mutually
exclusive components of our metabolism serve as
excellent target points for treatments and
prevention. GLP-1 agonists are currently
implemented as a new treatment method for type
2 diabetes due to their insulin-enhancing and
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satiety characteristics, and probiotic/antibiotic
treatments on patients have shown potential to
change human bacterial composition in ways that
are beneficial for regulating intestinal
permeability, inflammation, and glycemic
responses (Cani et al., 2008; Yadav et al., 2013).

Further investigations, specific to human
subjects, should be explored in order to assess the
true extent to which NNS impact incretin
secretion and alteration in the gut microbiota as
well as the inter-communication between these
two components.
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